PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search
BNF Chapter
BNF Paragraph
Please select a BNF Chapter.
Search Results : Menopausal disorders (HRT continuous combined - Menopausal disorders)
Records returned : 25 (on 05 Nov 2024 at 10:36:44). Return to search results for ' Menopausal disorders '.
Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Green
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Femoston tablets - 1st line for women requiring sequential combined therapy.
Green
Formulations :
- Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Bijuve capsules - 1st line for women requiring continuous combined therapy.
Green
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Femoston Conti - 1st line for women requiring continuous combined therapy.
06.04.01
Green
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Prescribe generically
06.04.01
07.02.01
Green
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Elleste Solo tablets - 1st line
Green
Formulations :
- Patches
ASPH
RSFT
SASH
SABP
Primary Care
Important
Estradiol patches 2nd line to tablets. No preferred patch recommendation has been made due to current stock shortages (Estraderm, Estradot, Evorel, FemSeven, Progynova TS)
Green
Formulations :
- Spray
ASPH
RSFT
SASH
SABP
Primary Care
Important
Lenzetto spray. Caution with higher than licensed doses.
Green (see narrative)
Formulations :
- Gel
ASPH
RSFT
SASH
SABP
Primary Care
Important
Oestrogel is the preferred gel option. Sandrena is an alternative option.
06.04.01
Green (see narrative)
Formulations :
- Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Prescribe generically.
Micronised progesterone oral capsules.
Green (see narrative)
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Kliofem tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
Green (see narrative)
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Kliovance tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
Green (see narrative)
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Elleste Duet Conti - 2nd line for women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line).
Green (see narrative)
Formulations :
- Patches
ASPH
RSFT
SASH
SABP
Primary Care
Important
Evorel Conti patches - preferred in women with risk factors for VTE or migraine. Otherwise use a 1st-line oral option.
Green (see narrative)
Formulations :
- Patches
ASPH
RSFT
SASH
SABP
Primary Care
Important
Femseven Conti patches - less preferred. Only use in the event of product shortages.
Green (see narrative)
Formulations :
- Patches
ASPH
RSFT
SASH
SABP
Primary Care
Important
Evorel Sequi patches 2nd-line. Preferred option in women with risk factors for VTE or migraine.
Green (see narrative)
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Elleste Duet tablets 2nd line. For women requiring sequential combined therapy but with poor cycle control on Femoston (1st-line).
Green (see narrative)
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Novofem tablets - Only use if there are product shortages with Elleste Duet
06.04.01
07.02.01
Green (see narrative)
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Progynova and Zumenon tablets NOT 1st line. Only prescribe where Elleste Solo tablets are unavailable.
06.04.01
07.03.02
Green (see narrative)
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
10mg tablets for adjunctive progestogen therapy
2nd line for endometrial protection in women who have abnormal bleeding on other HRT.
N/A
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Non Formulary
Formulations :
- Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Premique Low Dose - no longer recommended. Switch to a newer, lower risk formulation.
Non Formulary
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Recommend switching to a newer, lower risk formulation.
Non Formulary
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Trisequens tablets - consider changing to newer, 1st or 2nd line options.
Non Formulary
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Tridestra tablets - consider changing to a newer, 1st or 2nd line option.
Non Formulary
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Indivina tablets - consider changing to a newer, 1st or 2nd line option.
For information about the icons and status values within this site, please refer to the keys below.
Icon/Links Key
NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq form to be completed
NICE
Traffic Light Status Key
Red
Amber
Green
Black
Amber Star
Green (see narrative)
Non Formulary
See Below
N/A
Blue
Green - Black
See narrative
Do not initiate in new patients